Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: Characteristics and survival data

The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial.